article Open AccessTop 1% cited
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Annals of Oncology · 2018 · Vol. 29(7) · pp. 1541–1547
Gabriel N. Hortobágyi✉(The University of Texas MD Anderson Cancer Center)Salomon M. Stemmer(Tel Aviv University)H. A. Burris(Sarah Cannon)Yoon Sim Yap(National Cancer Centre Singapore)Gabe S. Sonke(The Netherlands Cancer Institute)Shani Paluch–Shimon(Sheba Medical Center)Mario Campone(Institut de Cancérologie de l'Ouest)Katarína Petráková(Masaryk Memorial Cancer Institute)Kim T. Blackwell(Duke Medical Center)Eric P. Winer(Dana-Farber Cancer Institute)W Janni(Universität Ulm)S. VermaPierfranco Conté(University of Padua)Carlos L. Arteaga(Vanderbilt University)David Cameron(Edinburgh Cancer Research)S. Mondal(Novartis (Switzerland))Faye Su(Novartis (Switzerland))Marshall G. Miller(Novartis (Switzerland))Mohamed Elmeliegy(Novartis (Switzerland))Caroline Germa(Novartis (Switzerland))Joyce O’Shaughnessy(Texas Oncology)
Advanced Breast Cancer TherapiesCancer-related Molecular PathwaysHER2/EGFR in Cancer ResearchLetrozoleMedicineHazard ratioInternal medicineClinical endpointBreast cancerOncologyMetastatic breast cancerPlaceboProgression-free survival
MeSH terms
LetrozoleAgedAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDouble-Blind MethodFemaleFollow-Up StudiesHumansLiver NeoplasmsLung NeoplasmsLymphatic MetastasisNeoplasm Recurrence, LocalPrognosisPurines
Funding
- Novartis Pharmaceuticals Corporation
Citations
845
FWCI
57.73
field-weighted impact
References
11
Percentile
100%
vs. same field & year
Citations per year
References
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
The Lancet Oncology · 2016 · 1,795 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.